Articles / Vitamin D is crucial, but supplementation and testing aren’t clearcut

Vitamin D’s role in bone health is well established, and emerging evidence suggests it has other benefits—but there is still contention around testing, supplementation, and target blood levels. While guidance is not always clear cut, it’s possible to make pragmatic clinical choices based on the evidence we already have, says epidemiologist Professor Rachel Neale, deputy director of the Population Health Program at QIMR Berghofer, an expert in vitamin D, sun exposure and skin cancer prevention.
Vitamin D is crucial for maintaining calcium homeostasis, which is essential for muscle function and bone mineralisation. It does this by increasing intestinal calcium absorption, reducing renal loss, and working alongside parathyroid hormone to reabsorb calcium from bones when necessary.
Despite this, the evidence for supplementation and fracture prevention is “not particularly solid,” Professor Neale says.
“The vast majority of randomised controlled trials show that vitamin D on its own has very little, if any, benefit for fracture reduction.”
This may be because many supplementation studies have been conducted in populations that were already vitamin D replete, she explains.
“Giving them more doesn’t seem to do very much for fracture outcomes.”
There is stronger evidence for vitamin D combined with calcium, particularly in people in residential aged care settings, she adds.
The definition of a sufficient blood concentration of 25-hydroxyvitamin D is controversial.
“That question has not been fully resolved,” Professor Neale says, noting measurement has historically been problematic.
“The assays have been both inaccurate and imprecise. And then we try and pull the data from all of those assays together to come up with some concentration, which becomes a very difficult proposition.”
“Sometimes people base it on the level at which parathyroid hormone plateaus. And that seems to be at about 50 nanomoles per litre. But some people believe that we really don’t end up with increased fracture risk until we get down to about 30, 25 nanomoles per litre,” she says.
Still others suggest a level of 75 nanomoles per litre (nmol/L) or more is sufficient, especially in older people who are at increased risk of falls and fractures, she says.
Australian guidelines currently define sufficiency in adults as 50 nmol/L.
Professor Neale says she used to agree with this, but her view has changed.
“And that’s because of the potential non-bone effects of vitamin D supplementation.”
Two recent major studies indicate that vitamin D supplementation may have extra-skeletal benefits, even in people with average 25-hydroxyvitamin D levels of approximately 70 nmol/L, Professor Neale explains.
“In the VITAL trial, there was evidence for reduced cancer mortality and autoimmune diseases. In the Australian D-Health trial, there was some evidence for reduced major cardiovascular events, particularly in people who were at high baseline risk of having an event. We saw reduced repeat antibiotic episodes, reduced lengthy hospitalisations for infection, and a somewhat reduced length of self-reported upper respiratory tract infections,” she says, acknowledging that these findings remain controversial.
“People argue about the interpretation of these because we measured lots of things, and you do find things by chance.”
“But my view is that there is some evidence for benefit, and the trials have shown that it’s safe,” she says.
“That’s why I’ve come to a fairly pragmatic solution that it’s not going to do us any harm. It may do us some benefit. So for many people, I think it’s not unreasonable to suggest a supplement.”
That said, there is not enough evidence to support routine population-wide government-funded food fortification or supplementation, she stresses.
People with deeply pigmented skin are at higher risk of deficiency because they synthesise vitamin D from sunlight less efficiently.
People who spend little time outdoors or cover most of their skin for cultural or religious reasons may also struggle to obtain adequate vitamin D from sun exposure.
“It’s really anyone who’s not receiving a vitamin D-effective dose of sunlight on most days of the week,” Professor Neale says.
In winter in Tasmania, for example, when almost half of the population (45.7%) is deficient, people typically need about an hour outdoors around midday wearing shorts and a T-shirt to generate sufficient vitamin D, she says.
However, weather conditions make this impractical, “which is why most people actually do need to take vitamin D supplements through winter in those southern states.”
People who work or study indoors are also at risk, she adds.
“Early morning and late afternoon sun exposures are not sufficient to give you adequate vitamin D production because you need UVB. So people who are office-bound are highly likely to be vitamin D deficient, and supplementation may be needed.”
Sunscreen use also plays a role, she says, citing findings from the Sun-D Trial, which randomised participants living from Queensland to Tasmania to either apply SPF50+ sunscreen routinely on days that the ultraviolet (UV) index was forecast to reach 3 or more (intervention group, n=312), or just at their discretion (control group, n = 316), for about a year.
“People in the sunscreen group were at 33% increased risk of being vitamin D deficient compared to the control group,” Professor Neale says.
There was a small difference in measured vitamin D levels between groups, she notes. “But the increase in summer was lower in the sunscreen group, which then translated into an increased risk of deficiency at the end of winter.”
“So if we are telling people that they should be consistently using sunscreen, then we also need to say this does increase your risk of vitamin D deficiency. So it is very much worth considering taking a vitamin D supplement.”
Vitamin D testing is widespread, expensive, and not necessarily well-targeted, Professor Neale says.
Medicare funds testing for people with deeply pigmented skin, in certain clinical situations, and in people with a chronic lack of sun exposure—although they do not define what this is.
Given the cost of testing, there is a case for initiating supplementation without it in people who seem unable to get outside enough or always protect their skin while outdoors, she says.
“Having said that, many clinicians find that patients are likely to be more compliant with their supplements if they’ve been tested and shown to be deficient.”
If you go ahead with testing, it’s essential to consider the season, she stresses.
“If you test somebody in late summer and they’ve got a 25D concentration of 60 nanomoles per litre or less, there’s a high probability that they will be deficient at the end of winter unless they change something.”
If a patient is vitamin D sufficient, repeat testing is unnecessary. If deficiency is identified and treated, reassessment at around three months is reasonable.
Routine monitoring is rarely required unless there are ongoing risk factors, compliance concerns or borderline results where seasonal decline may become clinically significant, she says.
Daily supplementation of 1000-2000 international units (IU) is reasonable for most people, Professor Neale advises. The upper tolerable limit is generally 4000 IU daily, although doses of 5,000 IU a day may be used to treat severe deficiency.
Daily supplementation is preferable to intermittent high-dose regimens, she says, explaining that the D-Health trial, which used monthly dosing, and an earlier Victorian trial that used annual dosing, indicated that large bolus doses could increase the risk of falls and fractures.
“So I think a daily dose is safer, and there’s some evidence that it’s more efficacious.”
Regarding formulations, there is better evidence for vitamin D3 (cholecalciferol) than for vitamin D2 (ergocalciferol), she adds.
While former messaging suggested that incidental daily sun exposure was sufficient to prevent vitamin D deficiency for most Australians, the reality is much more nuanced—with season, geography, time of day and clothing coverage all factoring in, Professor Neale says.
The Australian position statement on balancing the harms and benefits of sun exposure provides helpful guidance.
“For people who are at high risk of skin cancer, so that’s people with Fitzpatrick type one or two skin, or who have risk factors that put them at high risk of skin cancer—a family history of melanoma, lots of naevi, atypical naevi—we would suggest that the harms of sun exposure outweigh the benefits.”
“Those people should be protecting the skin very carefully when outdoors in the sun, ideally through clothing, shade, and avoiding those peak UV times, and meeting their vitamin D needs through supplementation.”
People with deeply pigmented skin are recommended to spend enough time outdoors with plenty of skin exposed when the UV index is 3 or more to get a vitamin D-effective dose of UV radiation. They do not need sun protection unless they’ll be spending extended time outdoors when the UV index is 3 or more.
People at intermediate risk of skin cancer (i.e. those who have olive or pale brown skin with no other risk factors), are advised to spend enough time outdoors with plenty of skin exposed to get a vitamin D-effective dose of UV radiation, and to use sun protection if spending more time outdoors than this.
The position statement has tables that provide general guidance for how many minutes people with different skin types in various locations need to maintain adequate vitamin D status.
Position statement | Balancing the harms and benefits of sun exposure
Healthy Bones Australia | Vitamin D & Bone Health
Cancer Council | SunSmart Global UV app (daily UV and sun protection alerts by location)

Oral GLP1s – What GPs Need to Know

The New Oral Medications for Obesity – A Practical Guide for GPs

Menstrual Migraine

GLP1s and Muscle Mass – What Does the Evidence Show?


A great extent
A moderate extent
Slightly
Not at all
Listen to expert interviews.
Click to open in a new tab
Browse the latest articles from Healthed.
Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.
Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.
